- PCI invests $365M in EU and US facilities for drug-device products.
- US expansion includes a 545,000 sq ft facility in Rockford, Illinois.
- New Dublin facility to start operations in Q4 2024, focusing on injectables and OSD.
- CityNorth Dublin facility to begin in Q3 2025, enhancing injectable packaging.
Investment Overview
PCI Pharma Services is investing over $365 million in expanding its infrastructure for the assembly and packaging of advanced drug delivery and drug-device combination products. This investment spans new and expanded facilities in Europe and North America, focusing on injectable formats. The initiative is part of PCI's global investment strategy, supported by recent business growth, and aims to accommodate future expansion.
US Expansion
In the United States, PCI plans a significant 545,000-square-foot expansion at its Rockford, Illinois campus. This facility will be dedicated to advanced drug delivery and drug-device combination assembly and packaging, enhancing PCI's capabilities in the region.
EU Developments
In Europe, PCI is expanding its operations with a new pharmaceutical packaging and device assembly facility near Dublin, Ireland. Scheduled to commence operations in Q4 2024, this facility will offer large-scale temperature-controlled storage and commercial-scale packaging for injectables and oral solid dose drug products. Additionally, PCI is constructing a new facility at its CityNorth Dublin campus, set to begin operations in Q3 2025, to increase capacity for the final assembly, labeling, and packaging of injectable drug products.
Enhanced Capabilities
Both new EU facilities will utilize PCI's expertise in operations, quality, engineering, and project management. They will feature scalable state-of-the-art equipment and production-adjacent services, such as in-house packaging design and analytical laboratories, to support manufacturability and streamline the commercial launch process. A new large-scale warehouse in Dublin, with cold chain storage capabilities, has also been opened to support customer demand, enhancing PCI's commercial packaging capabilities for the EU market.
